Biophytis and AskHelpU Join Forces in ALS Treatment Development
Biophytis SA, a clinical-stage biotechnology company, has announced a significant co-development agreement with AskHelpU, the largest patient association in China for those affected by Amyotrophic Lateral Sclerosis (ALS). This collaboration aims to assess the efficacy of BIO101, Biophytis' lead drug candidate, in treating ALS, a severe and progressive neuromuscular disease.
The Promise of BIO101
BIO101, currently under development for other indications such as sarcopenia and obesity, represents a potential major therapeutic breakthrough for ALS patients. The agreement outlines a pathway from promising preclinical results to a larger-scale clinical phase, contingent on establishing a proof of concept.
Leveraging Expertise for ALS
This partnership synergizes Biophytis' drug development capabilities with AskHelpU's extensive knowledge and network in the ALS community. AskHelpU will utilize top Chinese universities and research laboratories to conduct the necessary experiments, marking a unique opportunity for advancing ALS treatment.
ALS: A Global Health Challenge
ALS leads to the gradual paralysis of muscles, speech, and swallowing functions, with a global prevalence estimated between 4.1 and 8.4 patients per 100,000 inhabitants. The disease affects approximately 6,000 people in France, 31,000 in the United States, and around 200,000 in China, underscoring the urgent need for effective treatments.
AskHelpU's Commitment to ALS
Founded in 2019 by Cai Lei, a former JD.com Vice President, AskHelpU has become a pivotal force in the fight against ALS in China. The association has built a patient-centered data platform connecting over 15,000 individuals and has significantly raised awareness and support for ALS research and patient care.
A Shared Vision for Innovation
This collaboration between Biophytis and AskHelpU underscores a shared commitment to delivering innovative and sustainable solutions for improving patient care in the face of challenging diseases like ALS. By combining their strengths, the partners aim to accelerate the development of a much-needed therapeutic option for ALS patients worldwide.
For more information on Biophytis and its ongoing research, visit ,[object Object],.
